Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
December 22, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab – - Data from the Phase 2 portion of Kiniksa’s...
Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
November 09, 2020 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Reports Third Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
November 05, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
Rilonacept commercial launch in recurrent pericarditis anticipated in 1H 2021, if approved by the FDAMavrilimumab Phase 2 trial in GCA achieved primary and secondary efficacy endpoints with...
Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020
October 26, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Mavrilimumab reduced time-to-flare and increased sustained remission in Phase 2 giant cell arteritis clinical trial -- Primary and secondary efficacy endpoints achieved statistical significance...
Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
October 06, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to...
Kiniksa Announces U.S. Orphan Drug Designation for Mavrilimumab for the Treatment of Giant Cell Arteritis
September 15, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
June 17, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 17, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
June 10, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Rilonacept pivotal Phase 3 data in recurrent pericarditis expected in Q3 2020 - - Mavrilimumab Phase 2 data in GCA and KPL-404 Phase 1 data expected in Q4 2020 - - Management to provide a...
Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
June 08, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
May 11, 2020 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including earlier...